Literature DB >> 19663673

MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis.

Elias Zintzaras1, Dimitrios C Ziogas, Georgios D Kitsios, Afroditi A Papathanasiou, Joseph Lau, Gowri Raman.   

Abstract

AIMS: Pharmacogenetic studies investigating the relationship between MTHFR gene polymorphisms and response to fluorouracil-based chemotherapy in patients with colorectal cancer have produced inconclusive results. In an attempt to interpret these results, a meta-analysis of all eligible studies published up until January 2009 was carried out. MATERIALS &
METHODS: A total of ten studies relating MTHFR C677T and six studies relating MTHFR A1298C to the response to chemotherapy in patients with colorectal cancer were included in the meta-analysis and random effects pooled odds ratios were estimated. The heterogeneity between studies, the sources of potential bias and the consistency of genetic effects across ethnicities were explored. Cumulative and recursive cumulative meta-analyses were also performed.
RESULTS: For both the C677T and A1298C polymorphisms, the main analysis revealed nonsignificant heterogeneity and a lack of association under the allele contrast, the recessive and dominant models. The subgroup analysis by ethnicity did not change this pattern of results. The lack of stability of the relative change of odds ratio in the recursive cumulative meta-analysis for both polymorphisms indicated the need for more evidence to support a definite lack of association. There was no differential magnitude of the effect in large versus small studies.
CONCLUSION: The available evidence indicates that MTHFR C677T and A1298C gene polymorphisms cannot be considered as reliable predictors of response to fluorouracil-based chemotherapy in patients with colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19663673     DOI: 10.2217/pgs.09.59

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  15 in total

1.  Lack of association between MDR1 C3435T polymorphism and chemotherapy response in advanced breast cancer patients: evidence from current studies.

Authors:  Guodi Chen; Sheng Quan; Qiongge Hu; Liancong Wang; Xiaoping Xia; Jing Wu
Journal:  Mol Biol Rep       Date:  2011-12-09       Impact factor: 2.316

Review 2.  Pattern recognition for predictive, preventive, and personalized medicine in cancer.

Authors:  Tingting Cheng; Xianquan Zhan
Journal:  EPMA J       Date:  2017-03-09       Impact factor: 6.543

3.  MTHFR, MTR, and MTRR polymorphisms in relation to p16INK4A hypermethylation in mucosa of patients with colorectal cancer.

Authors:  Yvonne Wettergren; Elisabeth Odin; Göran Carlsson; Bengt Gustavsson
Journal:  Mol Med       Date:  2010-06-11       Impact factor: 6.354

Review 4.  Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-06-09

Review 5.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 6.  Germline oncopharmacogenetics, a promising field in cancer therapy.

Authors:  Chiara Pesenti; Milena Gusella; Silvia M Sirchia; Monica Miozzo
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

7.  Impact of the MTHFR C677T polymorphism on colorectal cancer in a population with low genetic variability.

Authors:  Luciano Delgado-Plasencia; Vicente Medina-Arana; Alberto Bravo-Gutiérrez; Julián Pérez-Palma; Hugo Álvarez-Argüelles; Eduardo Salido-Ruiz; Antonia M Fernández-Peralta; Juan J González-Aguilera
Journal:  Int J Colorectal Dis       Date:  2013-02-20       Impact factor: 2.571

8.  Genetic-based biomarkers and next-generation sequencing: the future of personalized care in colorectal cancer.

Authors:  Redecca Y Kim; Hua Xu; Samuel Myllykangas; Hanlee Ji
Journal:  Per Med       Date:  2011-05-01       Impact factor: 2.512

9.  Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy.

Authors:  Wen-Juan Li; Hua Jiang; Xin-Jian Fang; Hong-Ling Ye; Ming-Huan Liu; Yan-Wen Liu; Qian Chen; Li Zhang; Jin-Yu Zhang; Chun-Luan Yuan; Qiu-Yun Zhang
Journal:  Oncol Lett       Date:  2013-02-04       Impact factor: 2.967

10.  Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.

Authors:  Heidi Schwarzenbach
Journal:  EPMA J       Date:  2010-06-04       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.